• 

  How Down Syndrome Research Is Helping Scientists Understand Alzheimer’s
• 

  EU Approves Leqembi: Regulators Flip from ‘No’ to ‘Yes’ on Alzheimer’s Drug
• 

  Alzheimer’s Drug Trials: Do Drug Companies Warn You About Your Genetic Risk?
• 

  Trojan Horse: Carrying Alzheimer’s Antibodies Into the Brain
• 

  States Propose Bills to Make Private Insurers Cover Approved Alzheimer’s Drugs, Diagnostics
• 

  Curing Alzheimer’s Disease: Magic Bullet or Magic Shotgun Blast?
• 

  Alzheon Alzheimer’s Pill Misses the Mark in Phase 3 Trial, Hints at Benefit in MCI
• 

  After Two Phase 3 Trial Fails, Cassava Sciences Gives Up On Alzheimer’s Drugs
• 

  No Kisunla in Europe: Regulators Reject Lilly’s Alzheimer’s ‘Mab’ Drug
• 

  Might Xenon Gas Be Useful for Treating Alzheimer’s, as a New Study Suggests?
• 

  Australia Is Latest Country to Say ‘No’ to Leqembi
• 

  Remternetug: Alzheimer’s Prevention Trial Enrolls People as Young as 18
• 

  Leqembi Vs. Kisunla: An Alzheimer’s Drug Point-by-Point Comparison
• 

  Some Trial Volunteers Had Higher Risk of Brain Bleeds. Here’s Why Drugmakers Didn’t Tell Them
• 

  Axsome Asks FDA to Approve Questionable Alzheimer’s Agitation Drug

Previous345Next